Skip to content

Effects of hand hygiene product on the incidence of infection disease

Effects of hand hygiene product on the incidence of infection disease - A double-blind randomized controlled trial-

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCTs031210205
Enrollment
685
Registered
2021-07-21
Start date
2021-10-25
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

none none

Interventions

Active group: Use the hand hygiene product 5 times a day for 12 weeks. Placebo group: Use the placebo 5 times a day for 12 weeks. Both group: Record the physical condition in man agement app every day
Hand Hygiene product

Sponsors

Hori Satoshi
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1, Healthy men and women between 20 and 65 years old 2, Subjects who have written consent to participate in this study 3, Subjects who can implement standard infection from the informed consent.

Exclusion criteria

Exclusion criteria: 1, Subjects who have received medications or undergone surgery due to a cold, illness or injury requiring hospitalization within 2 months before this study. excluding medication for transient symptoms such as hay fever, stomach ache and headaches 2, Subjects with upper respiratory tract infections such as common cold or influenza infection when getting consent in this study. 3, Subjects with rough or itchy hands due to eczema or dermatitis 4, Subjects with allergy symptoms caused by drugs 5, Subjects who are or may be pregnant 6, Subjects who do not have a device that can do wnload and use the physical condition management application. 7, Subjects who do not agree to bear the communication costs associated with downloading and inputting the physical condition management application. 8, Healthcare workers involved in the examination and treatment of patients. 9, Subjects deemed unsuitable for inclusion in this study by the principal investigator.

Design outcomes

Primary

MeasureTime frame
Cumulative incidence rate of AURI-like symptoms

Secondary

MeasureTime frame
Cumulative incidence rate of ILI, Cumulative incidence rate of Flu and Cumulative incidence rate of COVID-19

Contacts

Public ContactSatoshi Hori

Juntendo University Hospital

shori@juntendo.ac.jp+81-3-3813-3111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026